NO312707B1 - Terapeutiske midler omfattende humane IL-4 mutantproteiner samt fremgangsmåte for fremstilling derav - Google Patents
Terapeutiske midler omfattende humane IL-4 mutantproteiner samt fremgangsmåte for fremstilling derav Download PDFInfo
- Publication number
- NO312707B1 NO312707B1 NO19941681A NO941681A NO312707B1 NO 312707 B1 NO312707 B1 NO 312707B1 NO 19941681 A NO19941681 A NO 19941681A NO 941681 A NO941681 A NO 941681A NO 312707 B1 NO312707 B1 NO 312707B1
- Authority
- NO
- Norway
- Prior art keywords
- hil
- proteins
- amino acid
- replaced
- amino acids
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 11
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 title abstract description 50
- 102000055229 human IL4 Human genes 0.000 title abstract description 50
- 102000008300 Mutant Proteins Human genes 0.000 title description 2
- 108010021466 Mutant Proteins Proteins 0.000 title description 2
- 230000008569 process Effects 0.000 claims abstract description 5
- 101100069857 Caenorhabditis elegans hil-4 gene Proteins 0.000 claims abstract 12
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 239000002299 complementary DNA Substances 0.000 claims description 18
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000002741 site-directed mutagenesis Methods 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 238000002703 mutagenesis Methods 0.000 claims description 4
- 231100000350 mutagenesis Toxicity 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 3
- 235000003704 aspartic acid Nutrition 0.000 claims 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 1
- 239000005557 antagonist Substances 0.000 abstract description 11
- 239000004031 partial agonist Substances 0.000 abstract description 8
- 108020004414 DNA Proteins 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229940028885 interleukin-4 Drugs 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 101150079601 recA gene Proteins 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4137333A DE4137333A1 (de) | 1991-11-13 | 1991-11-13 | Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung |
PCT/EP1992/002614 WO1993010235A1 (de) | 1991-11-13 | 1992-11-13 | Menschliche il-4 mutantenproteine |
Publications (3)
Publication Number | Publication Date |
---|---|
NO941681L NO941681L (no) | 1994-05-06 |
NO941681D0 NO941681D0 (no) | 1994-05-06 |
NO312707B1 true NO312707B1 (no) | 2002-06-24 |
Family
ID=6444719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19941681A NO312707B1 (no) | 1991-11-13 | 1994-05-06 | Terapeutiske midler omfattende humane IL-4 mutantproteiner samt fremgangsmåte for fremstilling derav |
Country Status (16)
Country | Link |
---|---|
US (1) | US5723118A (cs) |
EP (1) | EP0613499B2 (cs) |
JP (2) | JP3470970B2 (cs) |
KR (1) | KR100276410B1 (cs) |
AT (1) | ATE163196T1 (cs) |
AU (1) | AU671960B2 (cs) |
CA (1) | CA2123315C (cs) |
CZ (1) | CZ283467B6 (cs) |
DE (2) | DE4137333A1 (cs) |
DK (1) | DK0613499T4 (cs) |
ES (1) | ES2112340T5 (cs) |
GR (1) | GR3026600T3 (cs) |
HU (1) | HU217326B (cs) |
NO (1) | NO312707B1 (cs) |
SK (1) | SK280114B6 (cs) |
WO (1) | WO1993010235A1 (cs) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4423131A1 (de) * | 1994-07-01 | 1996-01-04 | Bayer Ag | Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4 |
GB9415379D0 (en) * | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
NZ292124A (en) * | 1994-07-29 | 1998-10-28 | Smithkline Beecham Plc | Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment |
IL126995A0 (en) * | 1996-06-14 | 1999-09-22 | Bayer Ag | T-cell selective interleukin-4 agonists |
US6335426B1 (en) | 1996-06-14 | 2002-01-01 | Bayer Corporation | T-cell selective interleukin-4 agonists |
US5986059A (en) * | 1996-06-14 | 1999-11-16 | Bayer Corporation | T-cell selective interleukin-4 agonists |
MY124565A (en) * | 1996-07-19 | 2006-06-30 | Bayer Corp | High-affinity interleukin-4-muteins |
US6180108B1 (en) * | 1998-12-10 | 2001-01-30 | Bayer Corporation | Vectors having terminal repeat sequence of Epstein-Barr virus |
DE10022258A1 (de) | 2000-05-08 | 2001-11-15 | Bayer Ag | Reinigung von Proteineinschlusskörpern durch Querstrom-Mikrofiltration |
EP3190126A1 (en) | 2000-05-26 | 2017-07-12 | Immunex Corporation | Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof |
GB0105360D0 (en) * | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
EP1314739A1 (en) * | 2001-11-22 | 2003-05-28 | Bayer Ag | Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines |
EP1382614A1 (en) * | 2002-07-15 | 2004-01-21 | Bayer HealthCare AG | Process for the purification of interleukin-4 and its muteins |
US7635754B2 (en) * | 2004-09-22 | 2009-12-22 | Aerovance, Inc. | Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same |
US20070009479A1 (en) * | 2005-06-17 | 2007-01-11 | Aerovance, Inc. | Methods for treating dermatitis using mutant human IL-4 compositions |
JP2010514409A (ja) * | 2006-06-21 | 2010-05-06 | アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ヒトの癌における鑑別式サイトカイン発現 |
WO2008003514A2 (en) * | 2006-07-06 | 2008-01-10 | Apogenix Gmbh | Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy |
EP2596802A1 (en) | 2011-11-23 | 2013-05-29 | PLS-Design GmbH | Pharmaceutical composition for treatment of allergic reactions |
EP2674168A1 (en) | 2012-06-14 | 2013-12-18 | PLS-Design GmbH | Modulation of effector T cell responses by local depletion of complement component C3 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5017691A (en) * | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
US5041381A (en) * | 1986-07-03 | 1991-08-20 | Schering Corporation | Monoclonal antibodies against human interleukin-4 and hybridomas producing the same |
DE68908431T2 (de) * | 1988-02-02 | 1993-12-23 | Schering Biotech Corp | Methode zur Verminderung der Immunglobulin-E-Reaktion. |
US5188827A (en) * | 1989-12-18 | 1993-02-23 | Schering Corporation | Use of interleukin-4- for lowering blood-cholesterol levels |
-
1991
- 1991-11-13 DE DE4137333A patent/DE4137333A1/de not_active Withdrawn
-
1992
- 1992-11-13 AU AU29282/92A patent/AU671960B2/en not_active Expired
- 1992-11-13 DE DE59209196T patent/DE59209196D1/de not_active Expired - Lifetime
- 1992-11-13 HU HU9401369A patent/HU217326B/hu unknown
- 1992-11-13 WO PCT/EP1992/002614 patent/WO1993010235A1/de active IP Right Grant
- 1992-11-13 ES ES92923502T patent/ES2112340T5/es not_active Expired - Lifetime
- 1992-11-13 CZ CZ941185A patent/CZ283467B6/cs not_active IP Right Cessation
- 1992-11-13 JP JP50897393A patent/JP3470970B2/ja not_active Expired - Fee Related
- 1992-11-13 KR KR1019940701592A patent/KR100276410B1/ko not_active IP Right Cessation
- 1992-11-13 CA CA002123315A patent/CA2123315C/en not_active Expired - Lifetime
- 1992-11-13 AT AT92923502T patent/ATE163196T1/de active
- 1992-11-13 SK SK554-94A patent/SK280114B6/sk not_active IP Right Cessation
- 1992-11-13 DK DK92923502T patent/DK0613499T4/da active
- 1992-11-13 EP EP92923502A patent/EP0613499B2/de not_active Expired - Lifetime
- 1992-11-13 US US08/232,289 patent/US5723118A/en not_active Expired - Lifetime
-
1994
- 1994-05-06 NO NO19941681A patent/NO312707B1/no not_active IP Right Cessation
-
1998
- 1998-04-10 GR GR980400796T patent/GR3026600T3/el unknown
-
2002
- 2002-09-30 JP JP2002287074A patent/JP2003174894A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SK55494A3 (en) | 1994-12-07 |
HUT66826A (en) | 1995-01-30 |
ES2112340T5 (es) | 2005-10-16 |
HU9401369D0 (en) | 1994-08-29 |
CA2123315C (en) | 2003-06-17 |
HU217326B (hu) | 1999-12-28 |
KR100276410B1 (ko) | 2000-12-15 |
WO1993010235A1 (de) | 1993-05-27 |
SK280114B6 (sk) | 1999-08-06 |
AU671960B2 (en) | 1996-09-19 |
US5723118A (en) | 1998-03-03 |
AU2928292A (en) | 1993-06-15 |
CZ118594A3 (en) | 1994-12-15 |
EP0613499B1 (de) | 1998-02-11 |
CZ283467B6 (cs) | 1998-04-15 |
DE4137333A1 (de) | 1993-05-19 |
ATE163196T1 (de) | 1998-02-15 |
NO941681L (no) | 1994-05-06 |
CA2123315A1 (en) | 1993-05-27 |
NO941681D0 (no) | 1994-05-06 |
EP0613499B2 (de) | 2005-03-30 |
EP0613499A1 (de) | 1994-09-07 |
DE59209196D1 (de) | 1998-03-19 |
GR3026600T3 (en) | 1998-07-31 |
DK0613499T4 (da) | 2005-04-18 |
JP3470970B2 (ja) | 2003-11-25 |
DK0613499T3 (da) | 1998-09-23 |
JP2003174894A (ja) | 2003-06-24 |
JPH07501522A (ja) | 1995-02-16 |
ES2112340T3 (es) | 1998-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO312707B1 (no) | Terapeutiske midler omfattende humane IL-4 mutantproteiner samt fremgangsmåte for fremstilling derav | |
EP0790255B1 (en) | Monoclonal antibodies directed to the cytotoxic lymphocyte maturation factor | |
JP4423313B2 (ja) | ナチュラルキラー刺激因子 | |
Atamas et al. | An alternative splice variant of human IL-4, IL-4 delta 2, inhibits IL-4-stimulated T cell proliferation. | |
EP0817847B1 (en) | Il-17 receptor | |
EP1173484B1 (en) | Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains | |
US8110187B2 (en) | Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto | |
US6433142B1 (en) | Megakaryocyte stimulating factors | |
JPH07508179A (ja) | ヒトインターロイキン−13 | |
AU8767698A (en) | Novel orphan receptor | |
JP4278710B2 (ja) | リンパ球化学誘引因子およびその用途 | |
US7273843B2 (en) | Methods of treating allergy by administering interleukin-17 receptor | |
US5338833A (en) | Carboxy terminal IL-6 muteins | |
JP3652365B6 (ja) | ナチュラルキラー刺激因子 | |
IL | In Activated Mast Cells, IL-1 Up-Regulates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |